Holen Sie sich die Stockscreener-App
2.105
2.47%
0.055
Schlusskurs vom Vortag:
$2.05
Offen:
$2.03
24-Stunden-Volumen:
703.72K
Relative Volume:
0.24
Marktkapitalisierung:
$721.12M
Einnahmen:
$796.85M
Nettoeinkommen (Verlust:
$30.44M
KGV:
25.00
EPS:
0.0842
Netto-Cashflow:
$93.88M
1W Leistung:
+9.98%
1M Leistung:
-7.87%
6M Leistung:
-54.14%
1J Leistung:
-49.01%
1-Tages-Spanne:
$2.01
$2.125
1-Wochen-Bereich:
$1.90
$2.125
52-Wochen-Spanne:
$1.77
$5.8099
Goodrx Holdings Inc Stock (GDRX) Company Profile
Firmenname
Goodrx Holdings Inc
Sektor
Branche
Telefon
(855) 268-2822
Adresse
2701 OLYMPIC BOULEVARD, SANTA MONICA
Compare GDRX vs VEEV, TEM, BTSG, HQY, WAY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
2.105 | 702.28M | 796.85M | 30.44M | 93.88M | 0.0842 |
VEEV
Veeva Systems Inc
|
174.31 | 28.42B | 3.20B | 908.91M | 1.39B | 5.4168 |
TEM
Tempus Ai Inc
|
47.68 | 8.47B | 1.27B | -245.03M | -245.36M | -1.4071 |
BTSG
Brightspring Health Services Inc
|
43.65 | 8.28B | 12.91B | 104.80M | 394.69M | 0.8769 |
HQY
Healthequity Inc
|
83.37 | 7.15B | 1.31B | 215.20M | 408.32M | 2.4627 |
WAY
Waystar Holding Corp
|
23.60 | 4.55B | 1.10B | 112.09M | 283.19M | 0.6096 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-27 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2026-01-22 | Herabstufung | Jefferies | Buy → Hold |
| 2025-12-09 | Eingeleitet | Barclays | Underweight |
| 2025-08-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-08-09 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-08-10 | Hochstufung | DA Davidson | Neutral → Buy |
| 2023-07-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | Eingeleitet | Citigroup | Buy |
| 2022-11-04 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-08-12 | Eingeleitet | DA Davidson | Neutral |
| 2022-06-10 | Herabstufung | Goldman | Buy → Neutral |
| 2022-06-06 | Fortgesetzt | BofA Securities | Buy |
| 2022-06-01 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-05-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-04-07 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-03-15 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | Bestätigt | Barclays | Overweight |
| 2022-03-01 | Bestätigt | BofA Securities | Neutral |
| 2022-03-01 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-01 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | Bestätigt | Evercore ISI | Outperform |
| 2022-03-01 | Bestätigt | Goldman | Buy |
| 2022-03-01 | Bestätigt | JP Morgan | Underweight |
| 2022-03-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-03-01 | Bestätigt | SVB Leerink | Outperform |
| 2022-01-07 | Eingeleitet | Goldman | Buy |
| 2021-12-21 | Eingeleitet | Stephens | Overweight |
| 2021-12-02 | Eingeleitet | Jefferies | Buy |
| 2021-08-31 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-08-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-04-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2021-01-25 | Eingeleitet | Guggenheim | Buy |
| 2020-11-19 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | Eingeleitet | Barclays | Equal Weight |
| 2020-10-19 | Eingeleitet | BofA Securities | Neutral |
| 2020-10-19 | Eingeleitet | Citigroup | Buy |
| 2020-10-19 | Eingeleitet | Cowen | Outperform |
| 2020-10-19 | Eingeleitet | Credit Suisse | Outperform |
| 2020-10-19 | Eingeleitet | Deutsche Bank | Hold |
| 2020-10-19 | Eingeleitet | Goldman | Neutral |
| 2020-10-19 | Eingeleitet | JP Morgan | Neutral |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-10-19 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2020-10-19 | Eingeleitet | UBS | Buy |
Alle ansehen
Goodrx Holdings Inc Aktie (GDRX) Neueste Nachrichten
Hims & Hers Advances a Consumer-Centric Digital Health Platform - TradingView
3 Promising Penny Stocks With Market Caps Under $2B - simplywall.st
GDRX PE Ratio & Valuation, Is GDRX Overvalued - Intellectia AI
GoodRx Holdings, Inc. Files Form 8-K Current Report with SEC – Company Information & Key Details - Minichart
GDRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
GoodRx Holdings announces board changes following director resignation By Investing.com - Investing.com India
GoodRx Holdings announces board changes following director resignation - investing.com
GoodRx Reshapes Board After Director Resignation and Reclassification - tipranks.com
GoodRx's Ian T. Clark resigns from Board; Wendy Barnes shifted between classes - TradingView
Director departs as GoodRx (GDRX) rebalances board classes and terms - Stock Titan
Wall Street Recap: Is GoodRx Holdings Inc showing insider buyingStock Surge & Weekly Return Optimization Plans - baoquankhu1.vn
GoodRx Holdings, Inc. (NASDAQ:GDRX) Short Interest Update - MarketBeat
GoodRx Holdings (GDRX) price target decreased by 38.27% to 2.87 - MSN
GDRX SEC FilingsGoodrx Holdings, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Movement Recap: Whats the MACD signal for GoodRx Holdings Inc2026 Volatility Report & Long Hold Capital Preservation Tips - baoquankhu1.vn
GoodRx Holdings, Inc. Files Form 8-K with SEC – Company Details, Stock Information, and Contact Data 23418195152 - Minichart
GoodRx chief accounting officer Romin Nabiey to resign effective April 3 - Investing.com Australia
GoodRx Chief Accounting Officer Resigns for New Opportunity - TipRanks
GoodRx chief accounting officer resigns to pursue other opportunities - StreetInsider
GoodRx's Romin Nabiey to Resign as Chief Accounting Officer, Effective April 3, 2026 - TradingView
GoodRx Holdings, Inc. Announces the Resignation of Romin Nabiey as Chief Accounting Officer, Effective April 3, 2026 - marketscreener.com
GoodRx (NASDAQ: GDRX) CAO Romin Nabiey to depart in 2026 - Stock Titan
GoodRx (GDRX): Vanguard disaggregates holdings after Jan 12, 2026 realignment - Stock Titan
How The Reset In Expectations Is Reframing The GoodRx Holdings (GDRX) Investment Story - Yahoo Finance
If You Invested $1,000 in Goodrx Holdings, Inc. (GDRX) - Stock Titan
Dow Update: Can GoodRx Holdings Inc expand its profit margins2026 Final Week & Weekly Hot Stock Watchlists - baoquankhu1.vn
GoodRx Holdings, Inc. Announces Dismissal of PwC as Independent Auditor in March 2026 - Minichart
GoodRx (GDRX) replaces PwC with KPMG as independent auditor for 2026 - Stock Titan
Morgan Stanley favors GoodRx (GDRX) and healthcare tech over managed care for 2026 citing strong market-beating potential - msn.com
GoodRx stock ticks up after launching weight-loss subscription service - MSN
GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Strategy Pivot Hits GoodRx - Los Angeles Business Journal
Lakewood Capital Management LP Decreases Position in GoodRx Holdings, Inc. $GDRX - MarketBeat
GoodRx (GDRX) director exercises 192K options and gifts 150K Class A shares - Stock Titan
GoodRx Holdings, Inc.Class A Common Stock (NQ: GDRX - The Chronicle-Journal
Published on: 2026-03-12 03:47:43 - baoquankhu1.vn
GoodRx (NASDAQ:GDRX) Shares Down 6%Time to Sell? - MarketBeat
GoodRx Holdings, Inc. announced that consumers paying with cash through its platform can enjoy up to 85% discounts on medications at more than 70,000 pharmacies across the United States. - Bitget
GoodRx (GDRX) Partners with Viatris for Major Medication Discoun - GuruFocus
GoodRx offers up to 85% discount on Viatris drugs (GDRX) - Seeking Alpha
GoodRx Partners with Viatris to Offer Up to 85% Savings on Established Brand Medications - ChartMill
GoodRx (GDRX) CAO converts RSUs to stock and withholds shares for taxes - Stock Titan
GoodRx: Losing Relevance With Consumers (Downgrade) (NASDAQ:GDRX) - Seeking Alpha
GoodRx (GDRX) Q4 2025 Earnings Call Transcript - AOL.com
Aug Technicals: How does GoodRx Holdings Inc perform in inflationary periods2025 Investor Takeaways & Verified Momentum Stock Ideas - baoquankhu1.vn
Aug Reactions: Is GoodRx Holdings Inc showing insider buyingMarket Movement Recap & Short-Term High Return Ideas - baoquankhu1.vn
GoodRx awards discretionary cash bonus to chief accounting officer - Investing.com UK
GoodRx awards discretionary cash bonus to chief accounting officer By Investing.com - Investing.com South Africa
GoodRx Awards Performance-Based Bonus to Chief Accounting Officer - TipRanks
GoodRx approves $72,918 discretionary bonus for Chief Accounting Officer Romin Nabiey - TradingView
GoodRx (GDRX) Board approves $72,918 bonus for Chief Accounting Officer - Stock Titan
Finanzdaten der Goodrx Holdings Inc-Aktie (GDRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Goodrx Holdings Inc-Aktie (GDRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Spectrum Equity VII, L.P. | 10% Owner |
Oct 15 '25 |
Sale |
4.00 |
23,771 |
95,103 |
0 |
0.61%
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):